By UnHideA Senior EditorsOriginal source:BernsteinFirst published on UnHideA:Original source date:
Key takeaway
The revenue decline remains primarily driven by pressure on core products, while lower expenses have temporarily improved the loss; a recovery in 2027 depends on a rebound in multiple products, and the report’s written assessment of 2026 revenue differs from its model forecast.
Why did revenue fall faster in the third quarter?
Zai Lab’s total revenue in 3Q26 was US$108.2 million, down 7% year over year and up 2% quarter over quarter; the year-over-year decline widened from 3% in 2Q26. Revenue was also about 4% below Bernstein’s expectation of US$113 million.
Two major products continued to weigh on revenue: Zejula revenue was US$32 million, down 24% year over year amid generic competition; Vyvgart revenue was US$24 million, down 13% amid NRDL price cuts and intensifying competition in the myasthenia gravis market. Together, the two accounted for about half of revenue.
Growth in some newer products provided a buffer: Nuzyra revenue was US$21 million, up 37% year over year and 23% quarter over quarter; KarXT, launched in June, also contributed revenue. The growth was not enough to offset the decline in major products.
Did the narrower loss reflect stronger operations or lower expenses?
The operating loss in 3Q26 was US$63 million, narrowing 18% from US$76 million in 2Q26; the operating margin improved from -72% in the prior quarter to -58%.
R&D expenses fell from US$62 million in 2Q26 to US$50 million, a quarter-over-quarter decline of 19%, and were an important reason for the narrower loss. At the same time, Optune revenue was only US$8 million, down 38% year over year and 36% quarter over quarter, indicating continued significant pressure on the product side; the improvement in the loss was not driven by revenue growth.
Which better represents the institution’s view: flat revenue in 2026 or the revenue forecast table?
Bernstein said that broadly flat revenue in 2026 could be expected; its view of a recovery in 2027 depends on higher use of Vyvgart’s subcutaneous formulation and KarXT under potential NRDL coverage, a recovery in Zejula sales, the easing of Xacduro supply constraints, and plans for local production in 2027.
However, the report’s financial table lists revenue forecasts of 2025A: US$460.16 million, 2026E: US$496.43 million, and 2027E: US$595.33 million. Based on the figures in the table, revenue in 2026 is up about 8% from 2025, which does not align with the written description of being “flat”; the model’s revenue for 2027 is up about 20% from 2026.
Can the pipeline make up for weak near-term growth? How does Bernstein value the stock?
Zoci reported a confirmed objective response rate of 81.8% in a first-line small-cell lung cancer study, with an estimated six-month progression-free survival rate of 81.9% and an incidence of related adverse events of grade 3 or higher of 9.1%. Bernstein said these data support advancing a global Phase III first-line study and expects a potential BLA filing in 2027; however, the firm also noted that near-term growth still lacks strong support, while Zoci remains an important potential re-rating driver for the portfolio.
Bernstein maintained its Market-Perform rating and a target price of 15 Hong Kong dollars; relative to the closing price of 18.01 Hong Kong dollars on 4 November 2026, this implies downside of about 17%. The target price is based on a valuation methodology combining DCF and a two-year forward price-to-sales ratio.